aryl
diketoacid
identifi
first
sarscov
ntpasehelicas
inhibitor
distinct
pharmacophor
featur
arylmethyl
group
attach
diketoacid
order
search
pharmacophor
space
around
diketoacid
core
three
class
dihydroxychromon
deriv
prepar
base
sar
studi
extend
featur
pharmacophor
model
sarscov
ntpase
helicas
propos
constitut
diketoacid
core
hydrophob
arylmethyl
substitu
free
catechol
unit
aryl
diketoacid
identifi
first
sarscov
ntpasehelicas
inhibitor
distinct
pharmacophor
featur
arylmethyl
group
attach
diketoacid
order
search
pharmacophor
space
around
diketoacid
core
three
class
dihydroxychromon
deriv
prepar
base
sar
studi
extend
featur
pharmacophor
model
sarscov
ntpase
helicas
propos
constitut
diketoacid
core
hydrophob
arylmethyl
substitu
free
catechol
unit
elsevi
ltd
right
reserv
sar
sever
acut
respiratori
syndrom
caus
coronaviru
sarscov
quickli
spread
nearli
countri
lead
infect
peopl
almost
death
worldwid
although
new
case
infect
report
sinc
sar
remain
global
health
threat
due
high
mortal
lack
therapeut
agent
previou
studi
identifi
aryl
diketoacid
adk
novel
antisar
agent
select
inhibit
ic
lm
duplex
dnaunwind
activ
sarscov
ntpasehelicas
without
signific
impact
atpas
activ
particular
interest
among
sarscov
ntpasehelicas
inhibitor
report
date
adk
exampl
distinct
structureact
relationship
provid
initi
featur
pharmacophor
model
compos
diketoacid
core
appropri
posit
arylmethyl
substitu
fig
studi
part
ongo
effort
delin
complet
pharmacophor
model
via
structur
variat
adk
design
sever
dihydroxychromon
deriv
bioisoster
adk
diketoacid
moieti
adk
poor
druglik
properti
replac
dihydroxychromon
scaffold
fig
dihydroxychromon
class
naturallyoccur
flavonoid
proven
stabil
safeti
share
similar
structur
motif
diketoacid
adk
two
phenol
hydroxyl
group
carbonyl
oxygen
serv
togeth
excel
mimic
diketoacid
function
fig
addit
compar
adk
substitu
attach
one
side
diketoacid
variou
function
introduc
side
dihydroxychromon
core
allow
extend
investig
pharmacophor
space
thu
design
novel
dihydroxychromon
deriv
arylmethyl
function
shown
play
critic
role
inhibitori
activ
adk
well
catechol
moieti
known
respons
variou
biolog
activ
flavonol
either
side
two
author
contribut
equal
work
fig
superimpos
adk
prepar
start
acetophenon
scheme
regioselect
benzyl
follow
acetyl
provid
fulli
protect
acetophenon
yield
two
step
underw
cycliz
yield
subsequ
oxid
give
aldehyd
yield
desir
dihydroxychromon
deriv
prepar
intermedi
reduct
amin
follow
deprotect
bbr
ch
cl
yield
free
protect
catechol
introduc
side
dihydrochromon
give
flavonol
deriv
scheme
free
catechol
deriv
quercetin
obtain
commerci
sourc
deriv
protect
catechol
function
posit
synthes
start
phenol
prepar
degrad
pentabenzyl
quercetin
yield
scheme
esterif
phenol
piperonyloyl
chlorid
gave
correspond
ester
cycliz
ester
presenc
k
co
phase
transfer
catalyst
follow
hydrogenolysi
provid
flavonol
yield
two
step
synthesi
dihydroxychromon
substitu
side
accomplish
select
alkyl
posit
flavonol
scheme
thu
peracetyl
follow
select
deacetyl
thiophenol
imidazol
nmp
gave
deprotect
flavonol
treatment
substitut
benzyl
bromid
aceton
presenc
k
co
room
temperatur
follow
methanolysi
provid
desir
compound
yield
synthes
dihydroxychromon
deriv
test
inhibitori
activ
atpas
duplex
dnaunwind
activ
helicas
phosphat
releas
assay
fretbas
assay
respect
clone
purif
sarscov
helicas
perform
previous
describ
like
adk
analogu
dihydroxychromon
deriv
show
signific
inhibit
helicas
atpas
activ
margin
inhibit
atpas
activ
lm
observ
two
disubstitut
dihydroxychromon
deriv
tabl
unexpectedli
compound
superimpos
adk
scaffold
inhibit
neither
atpas
duplex
dnaunwind
activ
sarscov
atpasehelicas
presum
high
flexibl
narylmethyl
methyl
substitu
compar
adk
counterpart
result
loss
inhibitori
activ
flavonol
protect
catechol
group
also
fail
show
inhibit
atpasehelicas
howev
flavonol
free
catechol
quercetin
select
inhibit
duplex
dnaunwind
activ
micromolar
rang
ic
lm
tabl
indic
possibl
role
free
catechol
moieti
bind
interact
target
enzym
presum
hydrogen
bond
donor
interestingli
substitut
arylmethyl
function
posit
remark
increas
activ
result
compound
tabl
inhibitori
activ
quercetin
also
improv
upon
introduct
arylmethyl
substitu
posit
tabl
noteworthi
flavonol
deriv
free
catechol
moieti
usual
two
three
time
activ
protect
catechol
counterpart
synergist
effect
two
substitu
attach
opposit
side
dihydrochromon
core
suggest
presenc
two
distinct
bind
site
target
enzym
hydrophob
arylmethyl
bind
site
catechol
bind
site
capabl
hydrogen
bond
interact
basi
studi
hypothes
extend
pharmacophor
model
fig
sarscov
ntpasehelicas
inhibitor
compos
three
key
compon
includ
diketoacid
core
hydrophob
site
free
catechol
moieti
summari
order
investig
pharmacophor
space
around
diketoacid
core
sarscov
ntpasehelicas
inhibitor
three
class
dihydroxychromon
deriv
prepar
scheme
synthes
commerci
avail
quercetin
reagent
condit
piperonyloli
chlorid
pyr
b
k
co
tbab
toulen
c
h
pdc
meohch
cl
scheme
synthes
dihydrochromon
deriv
substitu
side
core
diketoacid
mimic
reagent
condit
ac
pyr
b
phsh
imidazol
nmp
rt
c
r
ph
ch
br
k
co
aceton
rt
nh
meoh
rt
two
differ
substitu
arylmethyl
catechol
attach
opposit
end
synthes
dihydroxychromon
show
select
inhibit
duplex
dnaunwind
activ
sarscov
ntpasehelicas
moreov
inhibitori
activ
enhanc
combin
two
spatial
separ
substitu
indic
two
differ
bind
site
target
enzym
taken
togeth
extend
featur
pharmacophor
model
propos
constitut
diketoacid
core
hydrophob
arylmethyl
substitu
free
catechol
unit
structureact
studi
around
propos
pharmacophor
model
warrant
discoveri
potent
inhibitor
sarscov
ntpasehelicas
